Publications

Found 84 Results
Page 7 of 9

Letter to the Editor response: Nygaard et al.

The article by Nygaard and others (2016) proposes that applying batch correction approaches to microarray data from studies with unbalanced designs may inadvertently exaggerate the differences observed. In seeking to illustrate their point, Nygaard and others (2016) utilized…

Journal: Biostatistics


Identifying transcriptomic mechanisms of gemcitabine resistance pathways in pancreatic cancer.

Although pancreatic cancer is increasing in incidence, therapeutic options remain limited. Treatment with gemcitabine or a gemcitabine combination therapy is most common, although current combination therapies are challenged by toxicity….


Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Abstract Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the…

Journal: Proceeding of the National Academy of Science


Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain…

Journal: Human Molecular Genetics


Abstract 789: Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors

Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…


Similarities and differences in properties of glatiramer acetate (Copaxone®, Teva) versus polimunol (Synthon) using standard and emerging technologies: P11190

Background and aims: Copaxone ® is a non-biological complex drug (NBCD) for the treatment of multiple sclerosis. Recently, differently manufactured follow-on glatiramoid drug products (FOGAs) purported to be equivalent to…


BIOLOGICAL MARKERS FOR IDENTIFYING IBRUTINIB RESISTANCE IN PATIENTS HAVING MANTLE CELL LYMPHOMA AND METHODS OF USING THE SAME

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell…


Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors

Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…


Leveraging public genomic data to accelerate oncology therapeutic development in pancreatic cancer.

Pancreatic cancer has an estimated survival rate of only 5-6% (Siegel et al. 2015). The difficulty in early detection methods compounded by clinical trial failures precipitates the need for innovative…


Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory multiple…


Page 7 of 9